Inhibitory Effect of Minocycline on in Vitro Invasion and Experimental Metastasis of Mouse Renal Adenocarcinoma

Masumori, Naoya; Tsukamoto, Taiji; Miyao, Noriomi; Kumamoto, Yoshiaki; Saiki, Ikuo; Yoneda, Junya

doi:10.1016/s0022-5347(17)35268-0

Cited by 25 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study showed that minocycline inhibits in vitro invasion and experimental metastasis of mouse renal adenocarcinoma by inhibiting type IV collagen degradation (Masumori et al, 1994). However, the mechanism of action remains unclear.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma

et al. 2002

View full text Add to dashboard Cite

Since it has been widely recognised that renal cell carcinoma is refractory to standard therapies such as chemotherapy and radiotherapy, a new modality of treatment is needed. One of the potential alternative therapies for renal cell carcinoma may be inhibition of angiogenesis. In this study, we analysed the inhibitory effects of several potential agents on expression of angiogenic factors such as vascular endothelial growth factor and basic fibroblast growth factor, which are the main mediators in angiogenesis of renal cell carcinoma. We used medroxyprogesterone acetate, interferon-alpha, interferon-gamma, minocycline hydrochrolide and genistein, which are known to be antiangiogeneic. Northern blot analyses revealed that, among the five agents examined, genistein had a strong inhibitory effect on expression of vascular endothelial growth factor mRNA and basic fibroblast growth factor mRNA. Medroxyprogesterone acetate and interferon-alpha did not significantly decrease the level of either vascular endothelial growth factor mRNA or basic fibroblast growth factor mRNA. Interferon-gamma and minocycline had mild inhibitory effects on vascular endothelial growth factor mRNA and basic fibroblast growth factor mRNA expression. Genistein also inhibited both vascular endothelial growth factor mRNA and basic fibroblast growth factor mRNA expression after treatment with epidermal growth factor and hypoxia. These findings suggest that one of the mechanisms of the inhibition of angiogenesis by genistein is suppression of the expression of the angiogenic factors vascular endothelial growth factor and basic fibroblast growth factor in renal cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Our previous study showed that minocycline inhibits experimental metastasis of mouse renal adenocarcinoma (Masumori et al, 1994). In addition, minocycline inhibits angiogenesis in vivo and in vitro (Tamargo et al, 1991;Gilbertson-Beadling et al, 1995).…”

mentioning

confidence: 99%

Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Considering the potent inhibitory effects of tetracyclines against MMPs, their anti-cancer potential has been studied in a variety of cancers, including melanoma, lung, breast and prostate cancers (Lokeshwar, 2011). Minocycline has been shown to inhibit in vitro invasion and experimental pulmonary metastasis in mouse renal adenocarcinoma (MRAC-PM2) cells (Masumori et al, 1994). In addition, the i.p.…”

Section: Effects Of Minocycline On Cancermentioning

confidence: 99%

Minocycline: far beyond an antibiotic

Garrido-Mesa

Zarzuelo

Gálvez

2013

British J Pharmacology

763

597

View full text Add to dashboard Cite

Minocycline is a second‐generation, semi‐synthetic tetracycline that has been in therapeutic use for over 30 years because of its antibiotic properties against both gram‐positive and gram‐negative bacteria. It is mainly used in the treatment of acne vulgaris and some sexually transmitted diseases. Recently, it has been reported that tetracyclines can exert a variety of biological actions that are independent of their anti‐microbial activity, including anti‐inflammatory and anti‐apoptotic activities, and inhibition of proteolysis, angiogenesis and tumour metastasis. These findings specifically concern to minocycline as it has recently been found to have multiple non‐antibiotic biological effects that are beneficial in experimental models of various diseases with an inflammatory basis, including dermatitis, periodontitis, atherosclerosis and autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease. Of note, minocycline has also emerged as the most effective tetracycline derivative at providing neuroprotection. This effect has been confirmed in experimental models of ischaemia, traumatic brain injury and neuropathic pain, and of several neurodegenerative conditions including Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis and spinal cord injury. Moreover, other pre‐clinical studies have shown its ability to inhibit malignant cell growth and activation and replication of human immunodeficiency virus, and to prevent bone resorption. Considering the above‐mentioned findings, this review will cover the most important topics in the pharmacology of minocycline to date, supporting its evaluation as a new therapeutic approach for many of the diseases described herein.

show abstract

“…During recent years, doxycycline and minocycline have been shown to exert biological effects that are completely separate and distinct from their antimicrobial action. These effects include: inhibition of matrix metalloproteases (7), tumor-induced angiogenesis (8), malignant cell growth (9), and bone resorption (10) and depression of oxygen radical release from polymorphonuclear neutrophils (11,12), inhibition of inducible nitric oxide synthase (iNOS) [a putative mediator of inflammation (13,14)], and inhibition of protein tyrosine nitration by scavenging peroxynitrite (15). Experimental and clinical studies indicate that minocycline and doxycycline may be beneficial in treatment of rheumatoid arthritis and potentially in other inflammatory diseases (16)(17)(18).…”

mentioning

confidence: 99%

Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia

Yrjänheikki

Keinänen

Pellikka

et al. 1998

Proc. Natl. Acad. Sci. U.S.A.

925

734

View full text Add to dashboard Cite

Ischemic stroke is the most common lifethreatening neurological disease and has limited therapeutic options. One component of ischemic neuronal death is inf lammation. Here we show that doxycycline and minocycline, which are broad-spectrum antibiotics and have antiinf lammatory effects independent of their antimicrobial activity, protect hippocampal neurons against global ischemia in gerbils. Minocycline increased the survival of CA1 pyramidal neurons from 10.5% to 77% when the treatment was started 12 h before ischemia and to 71% when the treatment was started 30 min after ischemia. The survival with corresponding pre-and posttreatment with doxycycline was 57% and 47%, respectively. Minocycline prevented completely the ischemiainduced activation of microglia and the appearance of NADPH-diaphorase reactive cells, but did not affect induction of glial acidic fibrillary protein, a marker of astrogliosis. Minocycline treatment for 4 days resulted in a 70% reduction in mRNA induction of interleukin-1␤-converting enzyme, a caspase that is induced in microglia after ischemia. Likewise, expression of inducible nitric oxide synthase mRNA was attenuated by 30% in minocycline-treated animals. Our results suggest that lipid-soluble tetracyclines, doxycycline and minocycline, inhibit inf lammation and are neuroprotective against ischemic stroke, even when administered after the insult. Tetracycline derivatives may have a potential use also as antiischemic compounds in humans.

show abstract

Inhibitory Effect of Minocycline on in Vitro Invasion and Experimental Metastasis of Mouse Renal Adenocarcinoma

Cited by 25 publications

References 16 publications

Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma

Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma

Minocycline: far beyond an antibiotic

Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia

Contact Info

Product

Resources

About